Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung by Morabito, K M et al.
OPEN
Intranasal administration of RSVantigen-expressing
MCMV elicits robust tissue-resident effector and
effector memory CD8þ T cells in the lung
KM Morabito1,2, TR Ruckwardt1, AJ Redwood3, SM Moin1, DA Price4,5 and BS Graham1
Cytomegalovirus vectors are promising delivery vehicles for vaccine strategies that aim to elicit effector CD8þ Tcells.
Todeterminehow the routeof immunizationaffectsCD8þ T-cell responses in the lungsofmice vaccinatedwith amurine
cytomegalovirus vector expressing the respiratory syncytial virus matrix (M) protein, we infected CB6F1 mice via the
intranasal or intraperitoneal route and evaluated the M-specific CD8þ T-cell response at early and late time points. We
found that intranasal vaccination generated robust and durable tissue-resident effector and effector memory
CD8þ T-cell populations that were undetectable after intraperitoneal vaccination. The generation of these
antigen-experiencedcells by intranasal vaccination resulted in earlier T-cell responses, interferongammasecretion, and
viral clearance after respiratory syncytial virus challenge. Collectively, these findings validate a novel approach to
vaccination that emphasizes the route of delivery as a key determinant of immune priming at the site of vulnerability.
INTRODUCTION
Tissue-residentmemory T (TRM) cells have been found atmany
barrier sites, including the skin, gastrointestinal tract, and lung,
where they are poised to respond quickly to invading
pathogens.1–4 Unlike effector memory T (TEM) cells, which
may recirculate, TRM cells remain in the tissue and are often
identified by the expression of CD69, an early activation
marker, and CD103, an aE integrin, although the latter may
vary at different anatomical locations.1,5 TRM cells act as
antigen-specific sentinels and recruit innate and adaptive
immune cells into the infected tissue via the secretion of
cytokines and chemokines.6,7 They also proliferate rapidly and
kill infected cells, protecting directly against local chal-
lenge.3,4,5,8 It may therefore be important to elicit TRM cells
as part of an effective vaccination strategy.
Most respiratory virus infections are self-limited, and
replication-defective vaccine vectors only express antigen
for a short time. Immunization through brief exposure to
antigen in these settings typically leads to the generation of
central memory T (TCM) cells, which are long-lived but slow to
regain effector functions.9–11 In contrast, persistent vectors
such as cytomegalovirus (CMV) produce antigen for longer
periods of time and generate high frequencies of TEM cells,
which respond quickly to subsequent infection. CMV-based
vaccines have proven to be effective against simian immuno-
deficiency virus infection in Rhesus macaques.12 Although
vaccination did not lead to sterilizing immunity, challenged
animals were able to control viremia to undetectable levels.
Protection was attributed to the generation of CD4þ and
CD8þ TEM cells, whichwere able to clear virus fromperipheral
tissues.13 This approach has also been shown to protect against
other infectious diseases, including Ebola and tuberculosis, in
various animal models.12,14–18 Similar vectors have been
evaluated for therapeutic utility against cancer leading to
delayed growth or rejection of tumors and even for the purpose
of immunocontraception in mice.19–21
The phenomenon of memory inflation has been observed
in murine CMV (MCMV) infection, and large populations
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of CMV-specific memory T cells are found in elderly
humans.22–26 During MCMV infection, some antigen-specific
CD8þ T cells follow canonical memory kinetics, with an early
expansion phase followed by rapid contraction after viral
containment and the establishment of a low-level stable
memory population. In contrast, other antigen-specific
CD8þ T-cell populations undergo memory inflation and
continue to accumulate throughout chronic infection.22,25,27
Inflationary T cells typically display an effector (TEFF)
phenotype, with low expression of CD127 and CD62L and
high expression of the terminal differentiationmarker KLRG-1
(KLRG-1þ TEFF).22,23,25,27–30 This unique phenomenon,
which leads to sustained levels of functional MCMV-specific
CD8þ T cells, may provide an advantage for vaccination.
In this study, we investigated how the route of administration
affects the generation of CD8þ T-cell responses following
immunization with an MCMV vector expressing the respira-
tory syncytial virus (RSV)matrix (M) protein (MCMV-M).31,32
We show that intranasal (IN) vaccination with MCMV-M
generates a robust and durable tissue-resident memory
population with a TEFF/TEM phenotype that is absent in mice
vaccinated via the intraperitoneal (IP) route. Furthermore,
tissue-resident memory CD8þ T cells generated by IN
vaccination respond rapidly upon antigen re-exposure, leading
to lower viral loads after RSV challenge.
RESULTS
Vaccination with MCMV-M induces an inflationary
M-specific CD8þ T-cell response
We first evaluated whether vaccination with a recombinant
MCMV vector expressing the RSVMprotein could generate an
M-specific CD8þ T-cell response in the lungs. CB6F1 mice
were infected with RSV IN or vaccinated withMCMV-M IN or
IP. The percentage of CD8þ T cells specific for the DbM187–195
epitope (M-specific) was determined using tetramer staining
and flow cytometry at week 1 and week 6 post-infection in the
lungs.Mice infected with RSV showed a peak response of 6.25%
(Figure 1), which decreased after 6 weeks to 0.84% (Po0.01),
consistent with memory contraction. In contrast, mice infected
with MCMV-M mounted an M-specific CD8þ T-cell
response that increased between week 1 and week 6 post-
infection, consistent with MCMV-driven memory inflation.27
At 6 weeks post-infection, mice vaccinated IN with MCMV-M
had significantly more M-specific CD8þ T cells in the lungs
compared with mice infected with RSV (Po0.0001). Inter-
estingly, despite an identical dose of MCMV-M, mice
vaccinated IN also had substantially higher frequencies of
M-specific CD8þ T cells in the lungs at the same time point
compared with mice vaccinated IP (22.72% vs. 1.98%,
Po0.0001).
IN vaccination generates more M-specific CD8þ T cells in
the lung parenchyma than IP vaccination
To determine whether IN vaccination generates more tissue-
tropic M-specific CD8þ T cells in the lungs, we used an
intravascular stainingmethod that exclusively labels leukocytes
in the blood, allowing us to distinguish between compart-
ments.33 Mice were vaccinated IN or IP with MCMV-M, and
CD8þ T-cell responses were evaluated in the lungs and spleen
at weeks 1, 6, 16, and 24 post-vaccination. Five minutes prior to
killing, mice were injected intravenously with 3 mg of fluoro-
chrome-labeled anti-CD45 antibody. Cells that stained
CD45IVþ were located in the blood and available for
immediate labeling following IV antibody administration,
and cells that were CD45IV were protected from IV antibody
labeling and categorized as being in the tissue. As expected, IN
administration of MCMV-M induced significantly greater
frequencies and absolute numbers of M-specific CD8þ T cells
in the lung parenchyma at weeks 6, 16, and 24 post-vaccination
compared with an equivalent dose of MCMV-M administered
IP (Po0.0001; Figure 2a and Supplementary Figure S1a
online). However, there were no significant differences in the
percentages or numbers of M-specific CD8þ T cells in the
blood between vaccination groups. In the IN group, M-specific
CD8þ T-cell frequencies in the blood and tissue increased
between week 1 and week 6 post-vaccination, but significance
was only achieved in the lung parenchyma (Po0.0001).
Similarly, the numbers of M-specific CD8þ T cells in the lung
tissue inflated significantly between week 1 and week 6 post-
vaccination (Po0.01; see Supplementary Figure S1a). As a
consequence, more M-specific CD8þ T cells were present in
the tissue compared with the blood of mice in the IN group at
weeks 6, 16, and 24 post-vaccination (Po0.01). In the IP group,
M-specific CD8þ T-cell numbers increased between week 1
and week 6 post-vaccination in the blood but not in the tissue
Figure 1 MCMV-M generates an M-specific CD8þ T-cell population
that inflates over time. Mice were infected with 2106 PFU of RSV via the
intranasal (IN) route or 6 105 PFU of MCMV-M via the IN or
intraperitoneal (IP) route. At week 1 (W1) and week 6 (W6) post-infection,
the percentage of M-specific CD8þ T cells in the lungs was determined
using tetramer staining and flow cytometry. Bars represent mean±s.e.m.
with five mice per group. ****Pr0.0001 and **Po0.01 by two-way
analysis of variance with Tukey’s post-test for multiple comparisons. Data
represent two independent experiments. MCMV-M, murine
cytomegalovirus vector expressing the respiratory syncytial virus matrix
(M) protein; RSV, respiratory syncytial virus.
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(Po0.001; see Supplementary Figure S1a). The frequencies of
M-specific CD8þ T cells in the spleen were not significantly
different between the IN and IP vaccination groups at any time
point (Figure 2b). In both groups, significant inflation of the
M-specific CD8þ T-cell population in the spleenwas apparent
from week 1 to week 16 post-vaccination (Po0.01). These data
demonstrate that IN inoculation with MCMV-M establishes a
robust M-specific CD8þ T-cell population in the lung
parenchyma that is not generated by IP vaccination. In
contrast, equivalent systemic responses are induced in the
blood and spleen irrespective of themode of delivery, indicating
that the increase in local tissue responses by IN vaccination is
not at the expense of systemic immunity.
IN vaccination with MCMV-M induces a tissue-resident
memory M-specific CD8þ T-cell population
Next, we determined whether the induced tissue-tropic
CD8þ T cells expressed CD69, an early activation marker
Figure 2 IN vaccination generatesmoreM-specific CD8þ T cells in the lung parenchyma than IP vaccination. At weeks 1 (W1), 6 (W6), 16 (W16), and
24 (W24) post-vaccination with MCMV-M via the IN or IP route, mice were injected IV with anti-CD45 antibody 5min prior to killing to identify cells in the
blood (black) or tissue (gray). M-specific CD8þ T cells were identified by tetramer staining and flow cytometry. (a,b) Percentage of M-specific CD8þ
T cells in the tissue and blood of the lungs in a and spleen in b. (c) Expression of CD69 and CD103 on M-specific CD8þ T cells in the lung tissue at
16weeks post-vaccination. The percentage of CD8þ T cells in each quadrant is indicated. (d) Total number of CD69þCD103þ andCD69þCD103
M-specific CD8þ T cells in the lung tissue at 16 weeks post-vaccination with MCMV-M or infection with RSV. (e) Expression of CD69 and CD103 on
M-specific CD8þT cells in the lung tissue at 24 weeks post-vaccination. (f) Total number of CD69þCD103þ and CD69þCD103 M-specific CD8þ
T cells in the lung tissue at 24 weeks post-vaccination with MCMV-M. Bars represent mean±s.e.m. with five mice per group. ****Pr0.0001 by two-way
analysis of variance with Tukey’s post-test for multiple comparisons. Data represent two independent experiments. IN, intranasal; IP, intraperitoneal;
MCMV-M, murine cytomegalovirus vector expressing the respiratory syncytial virus matrix (M) protein; RSV, respiratory syncytial virus.
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typical of TRM cells, and CD103, an aE integrin commonly
used to delineate homing potential. At weeks 16 and 24
post-vaccination with MCMV-M via the IN or IP route, we
evaluated the expression of these markers on M-specific
CD8þ T cells identified within the lung parenchyma on the
basis of protection from intravascular staining. In the IN group,
61.8% of M-specific CD8þ T cells in the lung parenchyma
expressed both CD69 and CD103, while only 0.86% of
M-specific CD8þ T cells expressed both markers in the IP
group (Po0.0001; Figure 2c). This difference in the percentage
of TRM was maintained through week 24 post-vaccination
(Figure 2e; Po0.0001). We then determined the number of
M-specific CD8þ T cells expressing CD69 and CD103 in the
lung parenchyma in mice vaccinated IN or IP with MCMV-M
and mice infected with RSV. As CD103 is not ubiquitously
expressed on TRM cells, we also evaluated CD69 in isolation.We
found approximately 1,000-fold more CD69þCD103þ and
100-fold more CD69þCD103 M-specific CD8þ T cells in
the lung parenchyma of the IN group compared with the IP
group (Po0.0001, Figure 2d). Moreover, IN vaccination
with MCMV-M generated significantly greater numbers of
CD69þCD103þ and CD69þCD103 M-specific CD8þ
T cells compared with RSV infection (Po0.0001; Figure 2d).
The number of TRM generated by IN vaccination with MCMV-
M was maintained through week 24 post-vaccination
(Figure 2f). Similar numbers of these tissue-resident subsets
were present after RSV infection and IP vaccination with
MCMV-M. These data show that M-specific CD8þ TRM cells
in the lung are induced by vaccination with MCMV-M
delivered IN but not IP.
IN vaccination with MCMV-M augments the M-specific
CD8þ T-cell response via the induction of effector and
effector memory cells in the lung parenchyma and blood
Inflationary memory cells elicited by MCMV are comprised
predominantly of KLRG-1þ TEFF cells, together with a smaller
subset of TEM cells. We therefore evaluated the memory
phenotype of M-specific CD8þ T cells in the tissue and blood
of mice vaccinated IN or IP with MCMV-M. At weeks 1, 6, 16,
and 24 post-vaccination, M-specific CD8þ T cells were
identified by tetramer labeling after intravascular staining and
subsequent tissue harvest. Expression of CD44, CD127,
KLRG1, and CD62L were determined using flow cytometry.
We categorized the M-specific CD8þ T cells into phenotypic
subsets as follows: all, CD44þ ; central memory (CM),
CD127þ KLRG1 CD62Lþ ; effector memory (EM),
CD127þ KLRG1 CD62L ; effector (E), CD127
KLRG1 CD62L ; and KLRG1þ effector (KLRG1þ ),
CD127 CD62L KLRG1þ . Overall, IN vaccination
generated more TEFF and TEM M-specific CD8þ T cells
compared with IP vaccination at weeks 1 and 6 (Po0.0001;
Figure 3a, b) and weeks 16 and 24 (Po0.01, see
Supplementary Figure S2). Similar numbers of TCM and
KLRG1þ TEFF cells were present at weeks 6, 16, and 24. In the
tissue, IN vaccination generated more M-specific CD8þ
T cells of all phenotypes at week 1 through week 16 (Po0.05).
Although similar numbers of each phenotypic subset were
present in the blood at week 1 post-vaccination, there were
significantly more TEFF and TEM cells (Po0.0001) in the blood
of mice vaccinated via the IN route compared with the IP route
at week 6 (Figure 3b) and week 16 (see Supplementary Figure
S2). IP vaccination generated more TEFF, TEM, and KLRG1þ
TEFF cells in the spleen compared with IN vaccination at week
1 (Po0.01). At subsequent time points, however, there were
significantly more TEFF and TEM M-specific CD8þ T cells in
the spleen in the IN group compared with the IP group
(Po0.05). These data indicate that the route of vaccination
influences CD8þ T-cell phenotype not only in the blood and
tissue of the lung but also in the secondary lymphoid organs.
Inoculation into the lungs is necessary to generate lung-
tropic CD8þ T cells
Inoculation volume determines inoculum penetration into the
lungs.34–36 A volume of 20 ml will largely remain in the nose,
50 ml will enter the upper respiratory tract, and 100 ml will enter
the lower respiratory tract.34 To determine whether inoculation
into the lungs is necessary for the development of tissue-tropic
CD8þ T cells, we vaccinated mice IN with 1.2 105 PFU of
MCMV-M in a final volume of 20, 50, or 100 ml and determined
the percentage of M-specific CD8þ T cells in the lung tissue
and blood at week 6 post-vaccination. The tissue-tropic
population of M-specific CD8þ T cells was highly dependent
on inoculation volume (Figure 4a). Inoculation into the nose
(20 ml) was not sufficient to generate a response in the lung
parenchyma, whereas progressively larger tissue-tropic
M-specific CD8þ T-cell populations were observed with
inoculation volumes of 50 and 100 ml (Figure 4a).
IN vaccination leads to increased MCMV replication in the
lung
To test the hypothesis that vector replication is affected by the
route of inoculation, we vaccinatedmicewith 100 ml ofMCMV-
M via the IN or IP route. On days 2, 4, 8, 14, and 21 post-
vaccination,DNAwas extracted from the lungs, salivary glands,
and spleen, and viral loads were determined by quantitative
PCR for the IE1 gene.37 Mice vaccinated IN had significantly
higher MCMV genome copy numbers in the lungs at all time
points (Figure 4b; Po0.0001). IP vaccination was associated
with significantly higher viral loads in the spleen on day 2, but
no differences were detected on subsequent days. Viral
replication in the salivary glands was identical in both
vaccination groups. These data demonstrate that the route
of administration affects the distribution and kinetics of
MCMV replication. As there is greater MCMV replication in
the lungs of mice infected via the IN route, it is likely that more
antigen is presented at this site during acute infection and that a
larger pool of latently MCMV-infected cells persists during
chronic infection.
IN vaccination with MCMV-M leads to earlier antiviral T-cell
responses after RSV challenge
Based on the dramatic differences in tissue localization and
CD8þ T-cell memory phenotype, we hypothesized that mice
vaccinated via the IN route would more readily control RSV
ARTICLES
4 www.nature.com/mi
infection. At week 16 post-vaccination with MCMV-M or an
MCMV control, we challenged mice with RSV IN. On day 5
post-challenge, the lungs were harvested to measure viral load
using a plaque assay. Mice infected with the control MCMV via
either the IN or IP route had levels of RSV in their lungs similar
to those detected in unvaccinatedmice. In contrast, vaccination
with MCMV-M via either route lead to decreased viral loads
compared with controls (Po0.0001; Figure 5a). In addition,
mice vaccinated IN with MCMV-M had RSV viral loads that
were 100-fold lower compared with mice vaccinated via the IP
route (Po0.001). To confirm the role of CD8þ T cells in viral
clearance, we injected MCMV-M-vaccinated mice with a
depleting anti-CD8 antibody (2.43) on three consecutive days
prior to RSV challenge. We confirmed depletion of CD8þ T
cells in the blood and tissue of the lungs, spleen and the
posterior mediastinal lymph node on the day of RSV challenge,
and theCD8þ T-cell depletion wasmaintained through 5 days
post-RSV challenge (see Supplementary Figure S3). When
Figure 3 IN vaccination with MCMV-M augments the M-specific CD8þ T-cell response via the induction of effector and effector memory cells in the
lungparenchymaandblood.ThememoryphenotypeofM-specificCD8þ Tcells harvested from the indicated siteswasdeterminedatweek1andweek6
post-vaccinationwithMCMV-M.Micewere injected IVwith anti-CD45 antibody 5min prior to killing to identify cells in the blood or tissue. (a) Total number
of central memory (CM), effectormemory (EM), effector (E), and KLRG1þ effector (KLRG1þ ) cells at week 1 post-vaccination. (b) Total number of CM,
EM, E, and KLRG1þ cells at week 6 post-vaccination. Bars represent mean±s.e.m. with five mice per group. ****Pr0.0001, ***Po0.001, **Po0.01,
and *Po0.05 by two-way analysis of variance with Tukey’s post-test for multiple comparisons. Data represent two independent experiments. IN,
intranasal; IP, intraperitoneal.
Figure 4 Large volume IN vaccination leads to increased viral replication in the lung and is necessary for the generation of tissue-tropic M-specific
CD8þ T cells. (a) Mice were vaccinated IN with 1.2105 PFU of MCMV-M in a total volume of 20, 50, or 100 ml. The percentage of M-specific CD8þ T
cells in the lung at 6 weeks post-vaccination was determined using tetramer staining and flow cytometry. Bars represent mean±s.e.m. with fivemice per
group. (b)Quantification ofMCMVgenomecopy number by quantitativePCR in the lung, spleen, and salivary glands ofmice infected IN or IPwith 6 105
PFUofMCMV-M in 100 ml. Error bars represent s.e.m. Dotted line indicates limit of detection. ****Po0.0001 by two-way analysis of variancewith Tukey’s
post-test for multiple comparisons. IN, intranasal; IP, intraperitoneal; MCMV-M,murine cytomegalovirus vector expressing the respiratory syncytial virus
matrix (M) protein.
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CD8þ T cells were depleted, the difference in viral load
between the IN and IP vaccination group was abrogated,
indicating the CD8þ T-cell responses were responsible for the
difference in viral loads between mice vaccinated IN and IP
(Figure 5b).
To further support the role of TRM in mediating enhanced
protection, we treated mice that had been vaccinated 16 weeks
prior with MCMV-M by the IN or IP route with FTY720.
FTY720 is a sphingosine-1-phospate receptor 1 agonist and
prevents the egress of T cells from lymphoid organs. Treatment
with FTY720 reduces the number of recirculating naı¨ve and
TCM cells in the peripheral blood.
38 Mice were injected IP with
FTY720 daily for 3 days prior to RSV infection and throughout
infection. FTY720 treatment significantly reduced the number
of CD62Lþ M-specific CD8þ T cells in the blood of the lungs,
but not in the tissue of mice vaccinated with MCMV-M by the
IN or IP route (Po0.05; see Supplementary Figure S4b).
When vaccinated mice were treated with FTY720 prior to RSV
infection, mice vaccinated IN had significantly lower viral titers
in lung than mice vaccinated IP, further supporting the critical
role of M-specific CD8þ TRM cells in mediating viral control
(Po0.05, Figure 5d).
Figure 5 IN vaccination with MCMV-M leads to earlier antiviral responses compared to IP vaccination. Mice were challenged with 2106 PFU of RSV
either in the absence of prior vaccination or 16 weeks after IN or IP administration of MCMV or MCMV-M. On days 2–5 post infection, the lungs were
harvested for plaque assay and cytokine analysis. (a) Viral loads on day 5 post-infection determined by plaque assay. Dashed line indicates limit of
detection. (b) Viral loads on day 5 post-infection after CD8þ T-cell depletion. Dashed line indicates limit of detection. NS¼not significant. (c) Serial viral
loads after challenge with RSV. Dashed line indicates limit of detection. Error bars indicate s.e.m. with 5 mice per group. Asterisks indicate significant
differences betweenMCMV-M INandMCMV-M IP. (d) Viral loads onday 5post-infectionafter FTY720 treatment. Dashed line indicates limit of detection.
(e,f) Concentration of interferon gamma (IFNg) in e andmacrophage inflammatory protein-1beta (MIP-1b) in f in the lungs determined bymultiplex bead-
based array after challenge with RSV. Asterisks indicate significant difference between MCMV-M IN and MCMV-M IP. ****Po0.0001, ***Po0.001 and
*Po0.05 by one-way analysis of variance with Tukey’s post-test for multiple comparisons. IN, intranasal; IP, intraperitoneal; MCMV-M, murine
cytomegalovirus vector expressing the respiratory syncytial virus matrix (M) protein; RSV, respiratory syncytial virus.
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CD8þ TRM cells have been shown to respond rapidly to
antigen upon challenge. 6 We therefore hypothesized that IN
vaccination, which generates more TRM cells, would lead to
earlier antiviral responses. To evaluate early antiviral responses,
we challenged mice vaccinated 16 weeks previously with
MCMV-M or control MCMV. On day 2 through day 5 post-
challenge, we harvested the lungs to determine viral load by
plaque assay and cytokine levels by bead-basedmultiplex assay.
Mice vaccinated with MCMV-M via the IN route had lower
viral loads thanmice vaccinated via the IP route at day 3 though
day 5 (Po0.001; Figure 5c). In addition, mice vaccinated with
MCMV-M via the IP route had lower viral loads at day 4 and
day 5 compared with mice vaccinated with control MCMV via
either route (Po0.01). However, viral replication relative to
controls was suppressedmore effectively (Po0.0001) andmore
rapidly in mice vaccinated IN with MCMV-M. Peak RSV titers
were 10-fold lower in mice vaccinated with MCMV-M via the
IN route compared with mice vaccinated via the IP route and
nearly 100-fold lower compared with mice vaccinated with
control MCMV via the IN route (Po0.0001). There were no
significant differences in lung RSV titers at any time point after
challenge between mice immunized IN or IP with control
MCMV.
Next, we evaluated cytokine and chemokine levels in the
lungs of vaccinated mice after RSV challenge. Mice vaccinated
with MCMV-M via the IN route had significantly higher levels
of interferon gamma and macrophage inflammatory protein-
1beta on day 2 and day 3 post-challenge compared with mice
vaccinated via the IP route (Po0.001; Figure 5e, f). Cytokine
and chemokine levels decreased by day 4 and day 5 as viral loads
decreased. In mice vaccinated with MCMV-M via the IP route,
peak levels of interferon gamma andmacrophage inflammatory
protein-1beta occurred on day 4, one day later than IN
vaccinated mice. Mice vaccinated with control MCMV did not
show increased levels of interferon gamma and macrophage
inflammatory protein-1beta until day 5 post-challenge with no
difference between IN and IP vaccinated groups. These data
suggest that the TRM population generated by IN vaccination
with MCMV-M responds rapidly on challenge and mediates
better control of RSV.
DISCUSSION
In this study, we show that IN administration of an
MCMV vector expressing the M protein from RSV generates
a robust and durable M-specific CD8þ T-cell response.
This mode of vaccine delivery drives the accumulation
of CD8þ TRM cells in the lung parenchyma, most likely as
a consequence of greater antigen expression and viral
replication at the site of inoculation. These CD8þ TRM cells
mediate early antiviral responses that rapidly control infection
with RSV.
Here we show that local, rather than systemic delivery of a
viral antigen, leads to the generation of tissue-resident CD8þ
T cells in lung. Pulmonary inoculation has previously been
shown to be necessary for the generation of TRM cells in the
lung.39,40 Similar requirements have also been demonstrated
for other mucosal tissues, including the intestine and female
genital tract.41–43 Subcutaneous administration of rhCMV
elicits CD8þ T cells in bronchoalveolar lavage samples in
Rhesus macaques, suggesting that other routes of tissue
inoculation may also induce TRM.
44 IP vaccination with
MCMV-M generated an M-specific CD8þ T-cell population
that was primarily confined to the peripheral circulation,
consistent with previously published data showing IP admin-
istration of MCMV generates a non-perfusable CD8þ T-cell
population in the blood supply of the lungs, kidneys, and liver.45
Nonetheless, enhanced local immunity did not occur at the
expense of systemic immunity, because equivalent numbers of
M-specific CD8þ T cells were located in the spleen after IN
vaccination with MCMV-M. Interestingly, most of the
M-specific CD8þ T cells in the blood from both IN and
IP vaccination do not express CD62L and were not depleted
by FTY720 treatment, suggesting that this population
does not recirculate, but rather remains resident in the
marginating pool. This concept is consistent with a previous
study using immune-chimera mice that demonstrated antigen-
specific cells located in the vasculature of organs did not appear
to recirculate.46
TRM cells are poised to respond quickly to antigen encounter
and have been shown to act as immune sentinels via the rapid
production of cytokines and chemokines.7,47 Consistent with
these findings, we found that vaccination with MCMV-M via
the IN route, which elicited robust populations of TRM cells, led
to higher levels of interferon gamma and macrophage
inflammatory protein-1beta in the lungs of mice at earlier
time points post-challenge compared with mice vaccinated via
the IP route. These enhanced immune responses mediated
earlier clearance of RSV and lower peak viral titers, supporting
an important role for CD8þ TRM cells in pathogen control.
Although our data demonstrate that CD8þ Tcells play amajor
role in the increased protection seen with IN vaccination, the
role of CD4þ T cells in protection has not been elucidated.
The RSV M protein also encodes a CD4þ T-cell epitope, and
the contribution of CD4þ T cells specific for this epitope is
currently being evaluated.31
The route of inoculation affected not only the localization but
also the memory phenotype of vaccine-induced CD8þ T cells.
In mice vaccinated via the IP route, M-specific CD8þ T cells
displayed a predominant KLRG1þ TEFF phenotype. These
findings are consistent with previously published data showing
that inflationary memory populations derive mainly from
short-lived KLRG1þ TEFF cells that are constantly replen-
ished.45 However, when we administer the same vector by the
IN route, there is a significant shift in the phenotype of cells
elicited to the same epitope. Inmice vaccinated via the IN route,
therewere similar numbers ofKLRG1þ TEFF andTCM cells, but
also much larger populations of TEFF and TEM cells across all
anatomical locations. These populations may possess a better
capacity to respond to antigen re-exposure or longer lifespans
since they do not express KLRG1. These data emphasize the
critical role of the local environment of antigen-presentation in
the character of the immune response.
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Steinert et al.46 recently demonstrated that CD8þ T-cell
isolation from the tissue is biased by phenotype and location. As
our data compare two different vaccination routes and all
samples were treated identically, it is unlikely that our con-
clusions will be affected by such technological constraints
although we may underestimate the number of M-specific
CD8þ T cells. In addition, we were able to evaluate multiple
parameters by flow cytometry, which allowed us to probe
differences in memory phenotype that may have been missed by
microscopy.
While most vaccination schedules require multiple doses or
separate prime/boost constructs to minimize anti-vector
immunity, CMV vectors encoding inflationary epitopes may
require only a single dose to generate robust, durable
protection. In particular, TRM populations in the lung have
been shown to wane over time.39,48 In contrast, IN vaccination
with a single dose of MCMV-M generated a long-lived TRM
population, potentially overcoming the problem of waning
immunity in the lung. CD8þ T cells elicited by CMV infection
do not assume an exhausted phenotype, but instead remain
functional and protect in vivo.25,26,49 Moreover, persistent
antigen expression leads to the generation of CD8þ TEFF and
TEM cells, which respond more rapidly compared with the TCM
cells typically generated by acute vectors.
Collectively, we demonstrate that local delivery of a
persistent MCMV vector results in a high magnitude of
CD8þ effector TRM cells with a single dose leading to early viral
control and reduced viral loads. Sustained TRM populations will
likely be a key feature of vaccines that protect against infectious
diseases that are dependent on T-cell-mediated clearance for
protection such as tuberculosis, malaria, and HIV.
METHODS
Mice. Age-matched (6–10 weeks) female CB6F1/J mice (Jackson
Laboratories, BarHarbor,ME)were used in all experiments.Micewere
housed in the animal care facility at the National Institute of Allergy
and Infectious Diseases under specific-pathogen-free conditions and
maintained on standard rodent chow and water supplied ad libitum.
All studies were reviewed and approved by the National Institutes of
Health Animal Care and Use Committee.
Cell lines. Mouse embryonic fibroblasts (SCRC-1008) cell lines were
obtained from the ATCC and cultured in Advanced Dulbecco’s
modified Eagle’s medium (Invitrogen, Grand Island, NY) containing
8% or 10% fetal bovine serum or neonatal calf serum, 2mM glutamine,
10Uml l penicillin, 10 mgml 1 streptomycin and 0.1M HEPES.
HEp-2 cells were grown in Eagle’s minimal essential medium sup-
plemented with 10% fetal bovine serum, 2mM glutamine, 10Uml 1
penicillin, 10 mgml 1 streptomycin and 0.1 M HEPES.
Viruses and infections. Recombinant MCMVs were made using a
bacterial artificial chromosome (BAC) system.21 The RSVM sequence
was inserted into the IE2 gene of the K181Dm157 strain of MCMV by
two-step allele replacement. BACswere extracted from Escherichia coli
using aNucleoBond XtraMaxi Prep Kit (Macherey-Nagel, Bethlehem,
PA). Mouse embryonic fibroblasts cells were transfected with
recombinant BACs via calcium phosphate precipitation (Clontech,
Mountain View, CA). Viruses were passaged and single plaques
isolated by serial dilution. Single plaques were selected based on
excision of the BAC cassette by loss of GFP, and the presence of the
RSVM gene was confirmed by PCR. MCMV stocks were produced by
sonication of infected mouse embryonic fibroblasts cells. Mice were
infected IN or IP with 6 105 PFU of recombinant MCMV-M viruses
in 100 ml of 10% fetal bovine serum Dulbecco’s modified Eagle’s
medium, unless otherwise noted. RSV stocks for challenge were
generated from the A2 strain of RSV by sonication of infected HEp-2
monolayers.34 Mice were challenged IN with 2 106 PFU of RSV in
100 ml of 10% minimum essential media. All IN inoculations were
performed following anesthesia with isoflourane (3%). Mice were
killed by lethal overdose with pentobarbital (250mg kg 1).
Intravascular staining and flow cytometry. For intravascular
staining, mice were injected intravenously with 3 mg of anti-CD45
antibody (BD Biosciences, San Jose, CA). Lungs and spleen were
harvested after euthanasia with pentobarbital (250mg kg 1). Lym-
phocytes were isolated by physical disruption of tissue using a
GentleMACs machine (Miltenyi Biotec, San Diego, CA) followed by
Fico-LITE density gradient centrifugation. Isolated mononuclear cells
werewashedwith phosphate-buffered saline and resuspended in FACS
staining buffer (phosphate-buffered saline þ 1% fetal bovine serum
þ 0.05% sodium azide). Cells were stained with fluorochrome-labeled
antibodies for the lineage markers CD3 (145-2C11) and CD8 (53-6.7)
and the phenotypic markers CD44 (IM7), CD62L (MEL-14), CD127
(A7R34), KLRG-1 (2F1/KLRG1), CD69 (H1.2F3), and CD103 (M290)
(BD Biosciences or BioLegend, San Diego, CA). The amine viability
dye AquaBlue (Invitrogen) was used to identify dead cells. Antigen
specificity was determined using DbM187–195 tetramers conjugated to
APC (MBL,Woburn, MA). All samples were stained with a pre-mixed
antibody cocktail for 20min at 4 1C. Data were collected using an LSR
II flow cytometer (BD Biosciences) and analyzed with FlowJo software
(TreeStar, San Carlos, CA).
RSV plaque assay and cytokine analysis. Plaque assays were
performed as described previously.50 Lungs were harvested, weighed,
and frozen quickly in 10% minimum essential media supple-
mented with 2mM glutamine, 10Uml 1 penicillin, and 10 mgml 1
streptomycin. After thawing, lung tissue was dissociated using the
GentleMACs machine on program lung_02 (Miltenyi). Cell sus-
pensions were pelleted to remove cellular debris. Supernatants were
serially diluted and inoculated on 80% confluent HEp-2 cell mono-
layers in triplicate. Cells were incubated for 1 h at room temperature and
overlaid with 1% methyl cellulose in 10% minimum essential media.
After 4 days at 37˚C, cells were fixed with 10% buffered formalin and
stained with hematoxylin and eosin. Plaques were counted and
expressed asLog10PFUper g of lung tissue. The limit of detectionwas1.8
Log10 PFU per g. For cytokine analysis by multiplex bead-based array,
supernatants were sent to AssayGate (Ijamsville, MD).
CD8þ T-cell depletion and FTY720 treatment. Mice were vaccinated
with MCMV-M via the IN or IP route. After 16 weeks, 200mg of
anti-CD8 antibody (clone 4.23) in a total volume of 200ml was injected
IP for three consecutive days for CD8þ T-cell depletion studies. On
the third day, mice were challenged IN with 2 106 PFU of RSV. Five
days after challenge, the left lobe of the lung was harvested for
plaque assay. For FTY720 experiments, mice that had been vaccinated
with MCMV-M via the IN or IP route 16 weeks prior were given daily
IP injections of FTY720 at a dose of 1mg kg 1 (Sigma-Aldrich,
St Louis, MO) beginning 3 days prior RSV infection until killed. On
the fourth day of FTY720 treatment, mice were challenged with RSV
as described above.
Real-time quantitative PCR. Samples were processed as described
above for the plaque assay. DNA was extracted from 200 ml of
supernatant using a Nucleospin Blood Kit (Clontech). Real-time
quantitative PCR was performed for theMCMV IE1 gene as described
previously.37
Statistical analysis. Statistical analyses were performed using
one-way or two-way analysis of variances in GraphPad Prism
(La Jolla, CA).
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